ME00230B - 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni - Google Patents
2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oniInfo
- Publication number
- ME00230B ME00230B MEP-2008-461A MEP46108A ME00230B ME 00230 B ME00230 B ME 00230B ME P46108 A MEP46108 A ME P46108A ME 00230 B ME00230 B ME 00230B
- Authority
- ME
- Montenegro
- Prior art keywords
- pyrimidin
- pyrido
- pyridin
- cyclopentyl
- ylamino
- Prior art date
Links
- 201000010099 disease Diseases 0.000 claims abstract 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 13
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- -1 trifluoromethylalkyl Chemical group 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000002837 carbocyclic group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 229920002554 vinyl polymer Polymers 0.000 claims 6
- 229910020008 S(O) Inorganic materials 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 150000002825 nitriles Chemical class 0.000 claims 5
- 239000001301 oxygen Substances 0.000 claims 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 5
- 239000011593 sulfur Substances 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- QZDZRDATWGQUSE-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-(pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC=CC=3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 QZDZRDATWGQUSE-UHFFFAOYSA-N 0.000 claims 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- RNDSKWSXUGROBX-UHFFFAOYSA-N 6-acetyl-2-[[5-[bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCOC)CCOC)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 RNDSKWSXUGROBX-UHFFFAOYSA-N 0.000 claims 2
- JPJBKLUESOYNLD-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-(pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC1=CC=CC=N1 JPJBKLUESOYNLD-UHFFFAOYSA-N 0.000 claims 2
- JQDVILMFUIXCRM-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 JQDVILMFUIXCRM-UHFFFAOYSA-N 0.000 claims 2
- POJKMTSCTDNKEZ-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(C)=NC=C2C=C(Br)C(=O)N1C1CCCC1 POJKMTSCTDNKEZ-UHFFFAOYSA-N 0.000 claims 2
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 claims 2
- 108091008648 NR7C Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 claims 2
- 229960001171 acetohydroxamic acid Drugs 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- KECYKUOBQYTMFK-UHFFFAOYSA-N 2-[(6-acetyl-5-piperazin-1-ylpyridin-2-yl)amino]-8-cyclopentyl-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1C(C)=O)=CC=C1N1CCNCC1 KECYKUOBQYTMFK-UHFFFAOYSA-N 0.000 claims 1
- GNOBPPBWGCDWJR-UHFFFAOYSA-N 2-[[5-(2-aminoethylamino)pyridin-2-yl]amino]-6-bromo-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(NCCN)=CC=3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 GNOBPPBWGCDWJR-UHFFFAOYSA-N 0.000 claims 1
- VZEIYMGFCZFVGP-UHFFFAOYSA-N 2-[[5-(2-aminoethylamino)pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(NCCN)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 VZEIYMGFCZFVGP-UHFFFAOYSA-N 0.000 claims 1
- DGXNULHJVNJWJP-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(N)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 DGXNULHJVNJWJP-UHFFFAOYSA-N 0.000 claims 1
- WTZZGELFDNPANA-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)pyridin-2-yl]amino]-8-cyclopentyl-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(N)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 WTZZGELFDNPANA-UHFFFAOYSA-N 0.000 claims 1
- RFJNBZVTUKMOKC-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)pyridin-2-yl]amino]-8-cyclopentyl-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1N1CCC(N)C1 RFJNBZVTUKMOKC-UHFFFAOYSA-N 0.000 claims 1
- CIEGNEASRBFQLF-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)sulfonylpyridin-2-yl]amino]-6-bromo-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)S(=O)(=O)N3CC(N)CC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 CIEGNEASRBFQLF-UHFFFAOYSA-N 0.000 claims 1
- QYBHBZQEIJFIID-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)sulfonylpyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(N)CCN1S(=O)(=O)C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 QYBHBZQEIJFIID-UHFFFAOYSA-N 0.000 claims 1
- YXHQPGZZOMKDKV-UHFFFAOYSA-N 2-[[5-(3-aminopyrrolidin-1-yl)sulfonylpyridin-2-yl]amino]-8-cyclopentyl-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCC(N)C1 YXHQPGZZOMKDKV-UHFFFAOYSA-N 0.000 claims 1
- KRWHAQTXQAMXTB-UHFFFAOYSA-N 2-[[5-(azepan-1-yl)pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCCCC1 KRWHAQTXQAMXTB-UHFFFAOYSA-N 0.000 claims 1
- XIWCDJIWKPEYPF-UHFFFAOYSA-N 2-[[5-(azepan-1-yl)pyridin-2-yl]amino]-8-cyclopentyl-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CO)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCCCC1 XIWCDJIWKPEYPF-UHFFFAOYSA-N 0.000 claims 1
- ONLZGBFWCPBYLE-UHFFFAOYSA-N 2-[[5-(azetidin-1-yl)pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1N1CCC1 ONLZGBFWCPBYLE-UHFFFAOYSA-N 0.000 claims 1
- PKSPQJGYKMMCFO-UHFFFAOYSA-N 2-[[5-[3-(2-aminopropan-2-yl)pyrrolidin-1-yl]pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C(C)(N)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 PKSPQJGYKMMCFO-UHFFFAOYSA-N 0.000 claims 1
- GLIAQJVFZZCNRM-UHFFFAOYSA-N 2-[[5-[3-(benzenesulfonyl)propoxy]pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C=CC2=CN=C1NC(N=C1)=CC=C1OCCCS(=O)(=O)C1=CC=CC=C1 GLIAQJVFZZCNRM-UHFFFAOYSA-N 0.000 claims 1
- GDHUHDALUPEYNQ-UHFFFAOYSA-N 2-[[5-[bis(2-hydroxyethyl)amino]pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCO)CCO)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 GDHUHDALUPEYNQ-UHFFFAOYSA-N 0.000 claims 1
- RNSUPAGDKUJPOH-UHFFFAOYSA-N 2-[[5-[bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-6-bromo-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCOC)CCOC)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 RNSUPAGDKUJPOH-UHFFFAOYSA-N 0.000 claims 1
- FUPSONGCEPFMNO-UHFFFAOYSA-N 2-[[5-[bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-6-bromo-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCOC)CCOC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 FUPSONGCEPFMNO-UHFFFAOYSA-N 0.000 claims 1
- YDDZYJNEXVSNOR-UHFFFAOYSA-N 6-acetyl-2-[[5-(2-aminoethylamino)pyridin-2-yl]amino]-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC1=CC=C(NCCN)C=N1 YDDZYJNEXVSNOR-UHFFFAOYSA-N 0.000 claims 1
- QTZVWABNQLQVPQ-UHFFFAOYSA-N 6-acetyl-2-[[5-(3-aminopyrrolidin-1-yl)sulfonylpyridin-2-yl]amino]-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCC(N)C1 QTZVWABNQLQVPQ-UHFFFAOYSA-N 0.000 claims 1
- IQKCFVDADWUFCR-UHFFFAOYSA-N 6-acetyl-2-[[5-[3-(2-aminopropan-2-yl)pyrrolidin-1-yl]pyridin-2-yl]amino]-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCC(C(C)(C)N)C1 IQKCFVDADWUFCR-UHFFFAOYSA-N 0.000 claims 1
- WNFVIHQULLTZRP-UHFFFAOYSA-N 6-acetyl-2-[[5-[bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CCOC)CCOC)=CC=C1NC1=NC=C(C=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 WNFVIHQULLTZRP-UHFFFAOYSA-N 0.000 claims 1
- PNYDSWBFIYYAOD-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCOCC1 PNYDSWBFIYYAOD-UHFFFAOYSA-N 0.000 claims 1
- NVURUIMJTOVZJR-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2,6-dimethylmorpholin-4-yl)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)OC(C)CN1C(C=N1)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 NVURUIMJTOVZJR-UHFFFAOYSA-N 0.000 claims 1
- JDAYPETZCPTRRN-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 JDAYPETZCPTRRN-UHFFFAOYSA-N 0.000 claims 1
- RSOGDQWTVSCHQY-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 RSOGDQWTVSCHQY-UHFFFAOYSA-N 0.000 claims 1
- YAWYHLNWDSFVDA-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2-methoxyethoxymethyl)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(COCCOC)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 YAWYHLNWDSFVDA-UHFFFAOYSA-N 0.000 claims 1
- SUMIDHRKHFHCBN-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(2-methoxyethoxymethyl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(COCCOC)=CC=C1NC1=NC=C(C=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 SUMIDHRKHFHCBN-UHFFFAOYSA-N 0.000 claims 1
- OTNPSIGYUQFCTR-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(diethylamino)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CC)CC)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 OTNPSIGYUQFCTR-UHFFFAOYSA-N 0.000 claims 1
- GYICIMVQXWJGLP-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-(dimethylamino)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(C)C)=CC=C1NC1=NC=C(C(C)=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 GYICIMVQXWJGLP-UHFFFAOYSA-N 0.000 claims 1
- VEQOPAOFGZKFHM-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-2-[[5-[2-(diethylamino)ethoxy]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C(C)=O)C(=O)N2C3CCCC3)C2=N1 VEQOPAOFGZKFHM-UHFFFAOYSA-N 0.000 claims 1
- GGNIULHSXFVFEY-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCOCC1 GGNIULHSXFVFEY-UHFFFAOYSA-N 0.000 claims 1
- MJMAOJBJOJYBLM-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-morpholin-4-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCOCC1 MJMAOJBJOJYBLM-UHFFFAOYSA-N 0.000 claims 1
- MZBKJNDTXYIZDF-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-pyrrolidin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCCC1 MZBKJNDTXYIZDF-UHFFFAOYSA-N 0.000 claims 1
- CTQWHSWXTOSBOZ-UHFFFAOYSA-N 6-amino-2-[[5-(azepan-1-yl)pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(N)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCCCC1 CTQWHSWXTOSBOZ-UHFFFAOYSA-N 0.000 claims 1
- WXQRJGNEEAQTOZ-UHFFFAOYSA-N 6-amino-2-[[5-(azetidin-1-yl)pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(N)=CC2=CN=C1NC(N=C1)=CC=C1N1CCC1 WXQRJGNEEAQTOZ-UHFFFAOYSA-N 0.000 claims 1
- UOMYGSOEHPHNDW-UHFFFAOYSA-N 6-amino-2-[[5-[3-(2-aminopropan-2-yl)pyrrolidin-1-yl]pyridin-2-yl]amino]-8-cyclopentylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C(C)(N)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(N)C(=O)N2C3CCCC3)C2=N1 UOMYGSOEHPHNDW-UHFFFAOYSA-N 0.000 claims 1
- CCWNTMZZYJTKES-UHFFFAOYSA-N 6-amino-8-cyclopentyl-2-[[5-[(4-fluorophenyl)methylamino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(N)=CC2=CN=C1NC(N=C1)=CC=C1NCC1=CC=C(F)C=C1 CCWNTMZZYJTKES-UHFFFAOYSA-N 0.000 claims 1
- SIQIWCNODPCHCT-UHFFFAOYSA-N 6-benzyl-8-cyclopentyl-2-[[5-(3,3-dimethylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CNC(C)(C)CN1C(C=N1)=CC=C1NC1=NC=C(C=C(CC=2C=CC=CC=2)C(=O)N2C3CCCC3)C2=N1 SIQIWCNODPCHCT-UHFFFAOYSA-N 0.000 claims 1
- AFJKDJWTFSKEMJ-UHFFFAOYSA-N 6-benzyl-8-cyclopentyl-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(CC=2C=CC=CC=2)C(=O)N2C3CCCC3)C2=N1 AFJKDJWTFSKEMJ-UHFFFAOYSA-N 0.000 claims 1
- YCMUTOLJHOBKHY-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1N1CCOCC1 YCMUTOLJHOBKHY-UHFFFAOYSA-N 0.000 claims 1
- XTUCGPNYJALZMM-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[(5-morpholin-4-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCOCC1 XTUCGPNYJALZMM-UHFFFAOYSA-N 0.000 claims 1
- RRVRSGAVDBJKMR-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[(5-piperazin-1-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCNCC1 RRVRSGAVDBJKMR-UHFFFAOYSA-N 0.000 claims 1
- WGOXOVKLYPJIKG-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[(5-pyrrolidin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(Br)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCC1 WGOXOVKLYPJIKG-UHFFFAOYSA-N 0.000 claims 1
- CNGPKXNERYPGSQ-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 CNGPKXNERYPGSQ-UHFFFAOYSA-N 0.000 claims 1
- XSRCBEDXCLKGBI-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethoxymethyl)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(COCCOC)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 XSRCBEDXCLKGBI-UHFFFAOYSA-N 0.000 claims 1
- RJGGLQRGMFWGTR-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethoxymethyl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(COCCOC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 RJGGLQRGMFWGTR-UHFFFAOYSA-N 0.000 claims 1
- SGATYRVXUSFHRN-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(2-methoxyethylamino)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(NCCOC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 SGATYRVXUSFHRN-UHFFFAOYSA-N 0.000 claims 1
- KLTWTROREGKPHD-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 KLTWTROREGKPHD-UHFFFAOYSA-N 0.000 claims 1
- KPISUGGNPLIEMU-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)sulfonylpyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1S(=O)(=O)C(C=N1)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 KPISUGGNPLIEMU-UHFFFAOYSA-N 0.000 claims 1
- DDSHJIKUJXNHKG-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)sulfonylpyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1S(=O)(=O)C(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 DDSHJIKUJXNHKG-UHFFFAOYSA-N 0.000 claims 1
- GQVWQJOTSJFCHL-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(diethylamino)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(CC)CC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 GQVWQJOTSJFCHL-UHFFFAOYSA-N 0.000 claims 1
- RRKLALYYANVTSA-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(dimethylamino)pyridin-2-yl]amino]-5-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(C)C)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 RRKLALYYANVTSA-UHFFFAOYSA-N 0.000 claims 1
- RBQVAXVVMTZLFT-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-(dimethylamino)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(N(C)C)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 RBQVAXVVMTZLFT-UHFFFAOYSA-N 0.000 claims 1
- CCCDCVCYTAQWHL-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-[(4-fluorophenyl)methylamino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1CNC(C=N1)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 CCCDCVCYTAQWHL-UHFFFAOYSA-N 0.000 claims 1
- ZTLYXLBPZZWPHG-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-2-[[5-[2-(diethylamino)ethoxy]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(Br)C(=O)N2C3CCCC3)C2=N1 ZTLYXLBPZZWPHG-UHFFFAOYSA-N 0.000 claims 1
- CHQDKNRHNGRBFW-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCOCC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 CHQDKNRHNGRBFW-UHFFFAOYSA-N 0.000 claims 1
- GPSKAQVGRRENNK-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(5-morpholin-4-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)S(=O)(=O)N3CCOCC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 GPSKAQVGRRENNK-UHFFFAOYSA-N 0.000 claims 1
- DZCHDINWDGTTBZ-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 DZCHDINWDGTTBZ-UHFFFAOYSA-N 0.000 claims 1
- ZJVMZDYQLYDXNY-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(NC=3N=CC(=CC=3)S(=O)(=O)N3CCNCC3)=NC=C2C(C)=C(Br)C(=O)N1C1CCCC1 ZJVMZDYQLYDXNY-UHFFFAOYSA-N 0.000 claims 1
- CWYYESQEGIFPQG-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[(6-methyl-5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C=1C=C(N2CCNCC2)C(C)=NC=1NC(N=C12)=NC=C1C(C)=C(Br)C(=O)N2C1CCCC1 CWYYESQEGIFPQG-UHFFFAOYSA-N 0.000 claims 1
- SAFPZVKGPSYIMD-UHFFFAOYSA-N 6-bromo-8-cyclopentyl-5-methyl-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C(C)=C(Br)C(=O)N2C3CCCC3)C2=N1 SAFPZVKGPSYIMD-UHFFFAOYSA-N 0.000 claims 1
- IJKNQIIVZWJZOR-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-(3,3-dimethylpiperazin-1-yl)pyridin-2-yl]amino]-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CNC(C)(C)CN1C(C=N1)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 IJKNQIIVZWJZOR-UHFFFAOYSA-N 0.000 claims 1
- YBKVHGLXMPJGMW-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-(3,3-dimethylpiperazin-1-yl)pyridin-2-yl]amino]-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNC(C)(C)C1 YBKVHGLXMPJGMW-UHFFFAOYSA-N 0.000 claims 1
- UAQJRRMSPQQIKU-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)pyridin-2-yl]amino]-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1C(C=N1)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 UAQJRRMSPQQIKU-UHFFFAOYSA-N 0.000 claims 1
- FBRLMVUKRZGECH-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-(3,5-dimethylpiperazin-1-yl)pyridin-2-yl]amino]-6-ethylpyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1N1CC(C)NC(C)C1 FBRLMVUKRZGECH-UHFFFAOYSA-N 0.000 claims 1
- HWZVQBCJZYUUCA-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-[3-(3,5-dimethylpiperazin-1-yl)propyl-methylamino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(C)NC(C)CN1CCCN(C)C(C=N1)=CC=C1NC1=NC=C(C=CC(=O)N2C3CCCC3)C2=N1 HWZVQBCJZYUUCA-UHFFFAOYSA-N 0.000 claims 1
- YTQUGTPCYPXVEQ-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-[3-(ethylamino)pyrrolidin-1-yl]pyridin-2-yl]amino]-6-(hydroxymethyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1C(NCC)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 YTQUGTPCYPXVEQ-UHFFFAOYSA-N 0.000 claims 1
- WCYQLEMBUSZVBY-UHFFFAOYSA-N 8-cyclopentyl-2-[[5-[3-imidazol-1-ylpropyl(methyl)amino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C=1C=C(NC=2N=C3N(C4CCCC4)C(=O)C=CC3=CN=2)N=CC=1N(C)CCCN1C=CN=C1 WCYQLEMBUSZVBY-UHFFFAOYSA-N 0.000 claims 1
- PMDLISZAAKTUHC-UHFFFAOYSA-N 8-cyclopentyl-6-(1-ethoxyethenyl)-5-methyl-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=C)OCC)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCN(C)CC1 PMDLISZAAKTUHC-UHFFFAOYSA-N 0.000 claims 1
- AFNOMJNGXFOVCJ-UHFFFAOYSA-N 8-cyclopentyl-6-(ethoxymethyl)-2-[(5-morpholin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(COCC)=CC2=CN=C1NC(N=C1)=CC=C1N1CCOCC1 AFNOMJNGXFOVCJ-UHFFFAOYSA-N 0.000 claims 1
- CYWHSKRZQLMHLA-UHFFFAOYSA-N 8-cyclopentyl-6-(hydroxymethyl)-2-[(5-methylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(S(=O)(=O)C)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 CYWHSKRZQLMHLA-UHFFFAOYSA-N 0.000 claims 1
- CSRIIOZYVDOZIR-UHFFFAOYSA-N 8-cyclopentyl-6-(hydroxymethyl)-2-[(5-pyrrolidin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CO)=CC2=CN=C1NC(N=C1)=CC=C1N1CCCC1 CSRIIOZYVDOZIR-UHFFFAOYSA-N 0.000 claims 1
- OLEZGEUVISNETL-UHFFFAOYSA-N 8-cyclopentyl-6-(hydroxymethyl)-2-[[5-(2-methoxyethoxy)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(OCCOC)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 OLEZGEUVISNETL-UHFFFAOYSA-N 0.000 claims 1
- LUZIOVSCTPHSLJ-UHFFFAOYSA-N 8-cyclopentyl-6-(hydroxymethyl)-2-[[5-(2-methoxyethylamino)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CC(NCCOC)=CC=C1NC1=NC=C(C=C(CO)C(=O)N2C3CCCC3)C2=N1 LUZIOVSCTPHSLJ-UHFFFAOYSA-N 0.000 claims 1
- OZYCABBZTCNNQB-UHFFFAOYSA-N 8-cyclopentyl-6-ethyl-2-[(5-morpholin-4-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCOCC1 OZYCABBZTCNNQB-UHFFFAOYSA-N 0.000 claims 1
- WIZPNVWJXAAYER-UHFFFAOYSA-N 8-cyclopentyl-6-ethyl-2-[(5-piperazin-1-ylsulfonylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1S(=O)(=O)N1CCNCC1 WIZPNVWJXAAYER-UHFFFAOYSA-N 0.000 claims 1
- XQUSLYNLFSDUHT-UHFFFAOYSA-N 8-cyclopentyl-6-ethyl-2-[[5-[(4-fluorophenyl)methylamino]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC(N=C1)=CC=C1NCC1=CC=C(F)C=C1 XQUSLYNLFSDUHT-UHFFFAOYSA-N 0.000 claims 1
- YZESSMTVDITIOO-UHFFFAOYSA-N 8-cyclopentyl-6-ethyl-2-[[5-[2-(2-methoxyethoxy)ethoxy]pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(CC)=CC2=CN=C1NC1=CC=C(OCCOCCOC)C=N1 YZESSMTVDITIOO-UHFFFAOYSA-N 0.000 claims 1
- BWQCRPSZHRGYAS-UHFFFAOYSA-N 8-cyclopentyl-6-fluoro-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one;hydrochloride Chemical compound Cl.N1=C2N(C3CCCC3)C(=O)C(F)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 BWQCRPSZHRGYAS-UHFFFAOYSA-N 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 241000450599 DNA viruses Species 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000000442 hair follicle cell Anatomy 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000002464 muscle smooth vascular Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 150000003930 2-aminopyridines Chemical class 0.000 abstract 2
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 abstract 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 abstract 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35087702P | 2002-01-22 | 2002-01-22 | |
| PCT/IB2003/000059 WO2003062236A1 (en) | 2002-01-22 | 2003-01-10 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ME00230B true ME00230B (me) | 2011-02-10 |
| MEP46108A MEP46108A (en) | 2011-02-10 |
Family
ID=27613435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-461/08A MEP46108A (en) | 2002-01-22 | 2003-01-10 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
Country Status (52)
Families Citing this family (324)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| CA2417937A1 (en) * | 2000-08-04 | 2002-02-14 | Warner-Lambert Company | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
| ES2248233T3 (es) * | 2000-08-04 | 2006-03-16 | Warner-Lambert Company Llc | Procedimiento de preparacion de 2-(4-piridil)amino-6-dialquiloxifenil-pirido(2,3-d)pirimidin-7-onas. |
| PL366918A1 (en) * | 2001-02-12 | 2005-02-07 | F.Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| JP4166991B2 (ja) | 2001-02-26 | 2008-10-15 | 田辺三菱製薬株式会社 | ピリドピリミジンまたはナフチリジン誘導体 |
| US20030100572A1 (en) * | 2001-06-21 | 2003-05-29 | Ariad Pharmaceuticals,Inc. | Novel pyridopyrimidones and uses thereof |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| WO2004014907A1 (en) | 2002-08-06 | 2004-02-19 | F. Hoffmann-La Roche Ag | 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors |
| US7129351B2 (en) | 2002-11-04 | 2006-10-31 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| JP4666256B2 (ja) * | 2002-12-10 | 2011-04-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその医薬用途 |
| JP2006522756A (ja) | 2003-04-10 | 2006-10-05 | エフ．ホフマン−ラ ロシュ アーゲー | ピリミド化合物 |
| SI1648889T1 (sl) | 2003-07-11 | 2009-02-28 | Warner Lambert Co | Izetionatna sol selektivnega CDK4 inhibitorja |
| NZ544756A (en) | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| ES2386354T3 (es) | 2003-07-29 | 2012-08-17 | Xenon Pharmaceuticals Inc. | Derivados de piridilo y su uso como agentes terapéuticos |
| JP4616839B2 (ja) * | 2003-11-13 | 2011-01-19 | エフ．ホフマン−ラ ロシュ アーゲー | ヒドロキシアルキル置換ピリド−７−ピリミジン−７−オン類 |
| JP2007513967A (ja) * | 2003-12-11 | 2007-05-31 | セラヴァンス， インコーポレーテッド | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 |
| AU2005214352B2 (en) * | 2004-02-14 | 2009-11-12 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1718645A1 (en) * | 2004-02-18 | 2006-11-08 | Warner-Lambert Company LLC | 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones |
| WO2005094830A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| HRP20080018T3 (en) * | 2004-06-11 | 2008-01-31 | Japan Tobacco | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| MX2007008810A (es) * | 2005-01-21 | 2007-11-21 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| EP1845973B1 (en) * | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2006077425A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| WO2006090853A1 (ja) | 2005-02-25 | 2006-08-31 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| PE20061193A1 (es) * | 2005-03-25 | 2006-12-02 | Glaxo Group Ltd | DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38 |
| MY145281A (en) * | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
| SG195607A1 (en) | 2005-05-10 | 2013-12-30 | Incyte Corp | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| KR100734837B1 (ko) * | 2005-09-16 | 2007-07-03 | 한국전자통신연구원 | 다중 생체 인식 시스템 및 그 방법 |
| US20090221600A1 (en) * | 2005-09-28 | 2009-09-03 | Ashwani Kumar Verma | Pyrido-pyridimidine derivatives useful as antiinflammatory agents |
| CA2624965A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k.alpha. |
| WO2007044813A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
| US20090142337A1 (en) * | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
| EP2032134B1 (en) | 2006-05-09 | 2015-06-24 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| EP2069344A2 (en) * | 2006-09-08 | 2009-06-17 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| CN101573358B (zh) | 2006-09-15 | 2012-05-30 | 辉瑞产品公司 | 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途 |
| EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| WO2008150260A1 (en) * | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
| EP2084159A1 (en) * | 2006-10-16 | 2009-08-05 | GPC Biotech Inc. | Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors |
| JP2010509265A (ja) * | 2006-11-09 | 2010-03-25 | エフ．ホフマン−ラ ロシュ アーゲー | キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法 |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2009045503A1 (en) | 2007-10-05 | 2009-04-09 | Genzyme Corporation | Method of treating polycystic kidney diseases with ceramide derivatives |
| NZ586069A (en) | 2007-12-19 | 2012-05-25 | Amgen Inc | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| EP2278973B1 (en) | 2008-04-07 | 2011-11-02 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| MY171866A (en) | 2008-07-08 | 2019-11-05 | Incyte Holdings Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| KR20130140222A (ko) * | 2008-08-22 | 2013-12-23 | 노파르티스 아게 | Ｃｄｋ 억제제로서 피롤로피리미딘 화합물 |
| CA2738909A1 (en) | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| EP2341911A4 (en) * | 2008-10-01 | 2012-10-24 | Univ North Carolina | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE INHIBITORS OF KINASES DEPENDENT ON CYCLINES 4/6 |
| US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| JP5511942B2 (ja) | 2009-04-03 | 2014-06-04 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
| EP3025724B1 (en) | 2009-05-13 | 2018-07-11 | The University of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| US20120245344A1 (en) * | 2009-08-31 | 2012-09-27 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
| PH12012500692A1 (en) * | 2009-10-09 | 2012-11-12 | Afraxis Inc | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| AU2010315126B2 (en) | 2009-11-06 | 2015-06-25 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8889696B2 (en) | 2009-12-18 | 2014-11-18 | Temple University—Of the Commonwealth System of Higher Education | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| JP5918214B2 (ja) | 2010-04-13 | 2016-05-18 | ノバルティス アーゲー | がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| US8680099B2 (en) * | 2010-06-10 | 2014-03-25 | Afraxis Holdings, Inc. | 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders |
| EP2580320B1 (en) | 2010-06-14 | 2018-08-01 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| DK2600719T3 (da) | 2010-08-05 | 2014-12-15 | Univ Temple | 2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf |
| MX379532B (es) | 2010-10-25 | 2025-03-10 | G1 Therapeutics Inc | Inhibidores de cdk. |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| JP2013545758A (ja) | 2010-11-17 | 2013-12-26 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 増殖性キナーゼｃｄｋ４及びｃｄｋ６の阻害による虚血からの腎組織の保護 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
| CA2830516C (en) | 2011-03-23 | 2017-01-24 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| CN103747787A (zh) | 2011-05-27 | 2014-04-23 | 坦普尔大学 | 取代的2-亚苄基-2H-苯并[b][1,4]噻嗪-3(4H)-酮类、其衍生物及其治疗应用 |
| EA029768B1 (ru) * | 2012-03-14 | 2018-05-31 | Люпин Лимитед | Гетероциклильные соединения |
| EP2831080B1 (en) | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactam kinase inhibitors |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| NZ730134A (en) | 2012-06-13 | 2018-07-27 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| RU2679130C2 (ru) | 2012-07-11 | 2019-02-06 | Блюпринт Медсинс Корпорейшн | Ингибиторы рецептора фактора роста фибробластов |
| WO2014022830A2 (en) | 2012-08-03 | 2014-02-06 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9540367B2 (en) | 2012-08-17 | 2017-01-10 | Concert Pharmaceuticals, Inc. | Deuterated baricitinib |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US20140199728A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| WO2014128588A1 (en) | 2013-02-21 | 2014-08-28 | Pfizer Inc. | Solid forms of a selective cdk4/6 inhibitor |
| CA3152117A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| CN105407889B (zh) | 2013-03-15 | 2018-06-01 | G1治疗公司 | 针对Rb阳性异常细胞增殖的HSPC节制性治疗 |
| EP3492470A1 (en) | 2013-03-15 | 2019-06-05 | Concert Pharmaceuticals, Inc. | Deuterated palbociclib with improved metabolic stability |
| SG11201508328PA (en) | 2013-04-19 | 2015-11-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| CN104470921B (zh) * | 2013-05-17 | 2017-05-03 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| LT3395814T (lt) | 2013-10-25 | 2022-07-25 | Blueprint Medicines Corporation | Fibroblastų augimo faktoriaus receptoriaus inhibitoriai |
| EP4512480A3 (en) * | 2013-12-20 | 2025-05-07 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of cdk and erk inhibitors |
| US9949976B2 (en) | 2013-12-31 | 2018-04-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
| EP3091008B1 (en) | 2013-12-31 | 2018-06-27 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| US20150297607A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy |
| DK3148532T3 (en) | 2014-05-28 | 2021-04-26 | Piramal Entpr Ltd | Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer |
| JP6490215B2 (ja) | 2014-07-24 | 2019-03-27 | ベータ ファーマ，インコーポレイテッド | サイクリン依存性キナーゼ（ｃｄｋ）阻害剤としての２−ｈ−インダゾール誘導体およびその治療上の使用 |
| WO2016015598A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| EP3174878A4 (en) * | 2014-07-31 | 2017-12-27 | Sun Pharmaceutical Industries Limited | A process for the preparation of palbociclib |
| WO2016024232A1 (en) * | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| WO2016024249A1 (en) * | 2014-08-14 | 2016-02-18 | Sun Pharmaceutical Industries Limited | Crystalline forms of palbociclib |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN105111201B (zh) * | 2014-10-16 | 2017-01-11 | 上海页岩科技有限公司 | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CN105622638B (zh) * | 2014-10-29 | 2018-10-02 | 广州必贝特医药技术有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用 |
| WO2016066420A1 (en) * | 2014-10-29 | 2016-05-06 | Sandoz Ag | Crystalline forms of palbociclib monohydrochloride |
| CN105616418A (zh) * | 2014-11-07 | 2016-06-01 | 江苏豪森药业集团有限公司 | 含有细胞周期蛋白抑制剂的药物制剂及其制备方法 |
| HUE061672T2 (hu) | 2014-11-12 | 2023-08-28 | Seagen Inc | Glikán-interakcióban lévõ vegyületek és felhasználási módszerek |
| CN104496983B (zh) * | 2014-11-26 | 2016-06-08 | 苏州明锐医药科技有限公司 | 一种帕博西尼的制备方法 |
| CN104447743B (zh) * | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
| WO2016090257A1 (en) * | 2014-12-05 | 2016-06-09 | Crystal Pharmatech Inc. | Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib) |
| WO2016092442A1 (en) * | 2014-12-08 | 2016-06-16 | Sun Pharmaceutical Industries Limited | Processes for the preparation of crystalline forms of palbociclib acetate |
| CN105732615B (zh) * | 2014-12-31 | 2018-05-01 | 山东轩竹医药科技有限公司 | Cdk激酶抑制剂 |
| EP4205743A1 (en) | 2014-12-31 | 2023-07-05 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical composition and preparation method therefor |
| CN104610254B (zh) * | 2015-01-26 | 2017-02-01 | 新发药业有限公司 | 一种帕博赛布的低成本制备方法 |
| CZ201589A3 (cs) | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
| TWI690533B (zh) | 2015-02-12 | 2020-04-11 | 南北兄弟藥業投資有限公司 | Ｃｄｋ類小分子抑制劑的化合物及其用途 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| KR102632018B1 (ko) | 2015-02-20 | 2024-02-02 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서의 이환식 복소환 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
| EP3078663A1 (en) | 2015-04-09 | 2016-10-12 | Sandoz Ag | Modified particles of palbociclib |
| WO2016156070A1 (en) | 2015-04-02 | 2016-10-06 | Sandoz Ag | Modified particles of palbociclib |
| CN106795159B (zh) * | 2015-04-22 | 2018-12-28 | 江苏恒瑞医药股份有限公司 | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 |
| TWI696617B (zh) | 2015-04-28 | 2020-06-21 | 大陸商上海復尚慧創醫藥研究有限公司 | 特定蛋白質激酶抑制劑 |
| WO2016194831A1 (ja) * | 2015-05-29 | 2016-12-08 | 帝人ファーマ株式会社 | ピリド［３，４－ｄ］ピリミジン誘導体及びその薬学的に許容される塩 |
| KR102369405B1 (ko) * | 2015-06-04 | 2022-03-02 | 화이자 인코포레이티드 | 팔보시클립의 고체 투여 형태 |
| CN104892604B (zh) * | 2015-06-19 | 2016-08-24 | 北京康立生医药技术开发有限公司 | 一种cdk4抑制剂的合成方法 |
| CN106699785A (zh) * | 2015-07-13 | 2017-05-24 | 南开大学 | 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物 |
| US10526326B2 (en) | 2015-08-05 | 2020-01-07 | Ratiopharm Gmbh | Crystalline form and acetic acid adducts of palbociclib |
| CN105085517B (zh) * | 2015-08-06 | 2016-11-23 | 天津华洛康生物科技有限公司 | 一种结晶型帕博西尼游离碱水合物及其制备方法 |
| CN105130986B (zh) * | 2015-09-30 | 2017-07-18 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
| HU230962B1 (hu) | 2015-10-28 | 2019-06-28 | Egis Gyógyszergyár Zrt. | Palbociclib sók |
| CN106632311B (zh) | 2015-11-02 | 2021-05-18 | 上海科胜药物研发有限公司 | 一种帕博西尼晶型a和晶型b的制备方法 |
| KR20180088381A (ko) | 2015-11-12 | 2018-08-03 | 시아맙 쎄라퓨틱스, 인코포레이티드 | 글리칸-상호작용 화합물 및 사용방법 |
| CN105418603A (zh) * | 2015-11-17 | 2016-03-23 | 重庆莱美药业股份有限公司 | 一种高纯度帕布昔利布及其反应中间体的制备方法 |
| CN106810536A (zh) | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| EP3386981B1 (en) * | 2015-12-13 | 2021-10-13 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as anti-cancer agents |
| CN105418609B (zh) * | 2015-12-31 | 2017-06-23 | 山东大学 | 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用 |
| US10662186B2 (en) | 2015-12-31 | 2020-05-26 | Shanghai Pharmaceuticals Holding Co., Ltd. | Substituted pyrimidines as cyclin-dependent kinase inhibitors |
| CN106967061A (zh) * | 2016-01-13 | 2017-07-21 | 常州方楠医药技术有限公司 | 帕博西林的盐、晶型及其制备方法 |
| WO2017130219A1 (en) | 2016-01-25 | 2017-08-03 | Mylan Laboratories Limited | Amorphous solid dispersion of palbociclib |
| WO2017145054A1 (en) | 2016-02-24 | 2017-08-31 | Lupin Limited | Modified particles of crystalline palbociclib free base and process for the preparation thereof |
| WO2017161253A1 (en) | 2016-03-18 | 2017-09-21 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| CN107266421B (zh) * | 2016-04-08 | 2020-12-04 | 正大天晴药业集团股份有限公司 | 取代的苯并咪唑类衍生物 |
| CN107286180B (zh) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
| US10865204B2 (en) | 2016-04-22 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use |
| CN106336411B (zh) * | 2016-04-27 | 2018-03-06 | 上海医药集团股份有限公司 | Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途 |
| CN105949189B (zh) * | 2016-06-05 | 2017-09-22 | 童明琼 | 一种用于治疗乳腺癌的帕博西尼的制备方法 |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| KR20190025943A (ko) | 2016-07-01 | 2019-03-12 | 쥐원 쎄라퓨틱스, 인크. | 피리미딘-기재 항증식제 |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| WO2018007927A1 (en) | 2016-07-04 | 2018-01-11 | Dr. Reddy's Laboratories Limited | Process for preparation of palbociclib |
| EP3481825A1 (en) | 2016-07-07 | 2019-05-15 | Plantex Ltd. | Solid state forms of palbociclib dimesylate |
| AU2017311645B2 (en) | 2016-08-15 | 2021-05-27 | Pfizer Inc. | Pyridopyrimdinone CDK2/4/6 inhibitors |
| ES2966469T3 (es) | 2016-08-23 | 2024-04-22 | Eisai R&D Man Co Ltd | Terapias combinadas para el tratamiento del carcinoma hepatocelular |
| CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
| US10710999B2 (en) | 2016-10-07 | 2020-07-14 | Mylan Laboratories Limited | Polymorph of an intermediate for palbociclib synthesis |
| WO2018073574A1 (en) | 2016-10-20 | 2018-04-26 | Cipla Limited | Polymorphic forms of palbociclib |
| EP3528812B1 (en) | 2016-10-20 | 2020-12-30 | Pfizer Inc | Palbociclib for treating pah |
| CN106565707B (zh) * | 2016-11-03 | 2019-01-04 | 杭州科巢生物科技有限公司 | 帕博西尼新合成方法 |
| CA3041886A1 (en) | 2016-11-08 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| US20190275049A1 (en) | 2016-11-16 | 2019-09-12 | Pfizer Inc. | Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| TWI799399B (zh) | 2016-11-28 | 2023-04-21 | 日商帝人製藥股份有限公司 | 吡啶并〔３，４－ｄ〕嘧啶衍生物及其藥學上所容許之鹽 |
| US11261182B2 (en) * | 2016-11-28 | 2022-03-01 | Teijin Pharma Limited | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof |
| CN110382495B (zh) | 2016-12-16 | 2022-04-05 | 基石药业（苏州）有限公司 | Cdk4/6抑制剂 |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| CN108191857B (zh) * | 2017-01-24 | 2020-10-23 | 晟科药业（江苏）有限公司 | 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂 |
| US10729692B2 (en) * | 2017-02-26 | 2020-08-04 | Institute For Cancer Research | Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death |
| CN110809576B (zh) * | 2017-03-03 | 2022-08-30 | 奥克兰联合服务有限公司 | Fgfr激酶抑制剂和药物用途 |
| EP3589319A4 (en) | 2017-03-03 | 2021-07-14 | Seagen Inc. | COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE |
| MA47776A (fr) | 2017-03-16 | 2020-01-22 | Eisai R&D Man Co Ltd | Polythérapies pour le traitement du cancer du sein |
| CN108658855A (zh) * | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种含氮双环化合物及其制备方法和用途 |
| CN108658854A (zh) * | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种生物碱化合物及其制备方法和作为海洋防污剂的应用 |
| EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2018232235A1 (en) | 2017-06-16 | 2018-12-20 | Beta Pharma, Inc. | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| WO2019006393A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| EA036060B1 (ru) * | 2017-07-17 | 2020-09-21 | Пфайзер Инк. | Пиридопиримидиноновые ингибиторы cdk2/4/6 |
| EA202090402A1 (ru) | 2017-07-28 | 2020-05-19 | Синтон Б.В. | Фармацевтическая композиция, содержащая пальбоциклиб |
| CN109384767B (zh) * | 2017-08-08 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 |
| WO2019043504A1 (en) | 2017-08-31 | 2019-03-07 | Novartis Ag | METHODS OF SELECTING TREATMENT FOR PATIENTS WITH CANCER |
| CN107488175A (zh) * | 2017-09-04 | 2017-12-19 | 上海微巨实业有限公司 | 一种帕博西林关键中间体的制备方法 |
| US12043870B2 (en) | 2017-10-02 | 2024-07-23 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
| CN108586452A (zh) * | 2018-01-12 | 2018-09-28 | 重庆市碚圣医药科技股份有限公司 | 一种帕博西尼中间体的合成方法 |
| MX2020007959A (es) | 2018-01-29 | 2020-09-18 | Beta Pharma Inc | Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos. |
| CN108218861B (zh) * | 2018-02-05 | 2019-07-23 | 黑龙江中医药大学 | 一种预防和治疗糖尿病的药物及其制备方法 |
| JP7348665B2 (ja) | 2018-02-06 | 2023-09-21 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体 |
| CA3092003A1 (en) | 2018-02-27 | 2019-09-06 | Pfizer Inc. | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor |
| CR20200441A (es) | 2018-02-27 | 2021-03-15 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| ES2968899T3 (es) | 2018-05-14 | 2024-05-14 | Pfizer | Formulación de la solución oral |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| HUE064895T2 (hu) | 2018-05-24 | 2024-04-28 | Synthon Bv | Eljárás palbociklib elõállítására |
| PE20211807A1 (es) | 2018-07-05 | 2021-09-14 | Incyte Corp | Derivados de pirazina fusionados como inhibidores de a2a/a2b |
| CN112533596A (zh) | 2018-07-23 | 2021-03-19 | 豪夫迈·罗氏有限公司 | 用pi3k抑制剂gdc-0077治疗癌症的方法 |
| SG11202100429TA (en) | 2018-07-27 | 2021-02-25 | California Inst Of Techn | Cdk inhibitors and uses thereof |
| WO2020041770A1 (en) | 2018-08-24 | 2020-02-27 | G1 Therapeutics, Inc. | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
| JP6952747B2 (ja) | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ |
| JP2022504388A (ja) | 2018-10-08 | 2022-01-13 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｉ３ｋアルファ阻害剤およびメトホルミンを用いたがんの処置方法 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| CN113166148B (zh) * | 2018-12-07 | 2024-04-12 | 杭州英创医药科技有限公司 | 作为cdk-hdac双通路抑制剂的杂环化合物 |
| SG11202106635WA (en) | 2018-12-21 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and kinase inhibitor |
| WO2020140054A1 (en) | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| CA3124574A1 (en) * | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US20220125777A1 (en) | 2019-02-01 | 2022-04-28 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| SG11202108702XA (en) | 2019-02-15 | 2021-09-29 | Incyte Corp | Cyclin-dependent kinase 2 biomarkers and uses thereof |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| EP3976043A1 (en) | 2019-05-24 | 2022-04-06 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| CN113874036A (zh) | 2019-05-24 | 2021-12-31 | 辉瑞公司 | 使用cdk抑制剂的联合治疗 |
| CN112010844B (zh) * | 2019-05-31 | 2023-07-25 | 中国药科大学 | N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN112094272A (zh) | 2019-06-18 | 2020-12-18 | 北京睿熙生物科技有限公司 | Cdk激酶抑制剂 |
| CN113993505B (zh) * | 2019-06-20 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 一种药物组合物以及其制备方法 |
| CN110143948B (zh) * | 2019-06-21 | 2021-05-14 | 上海博悦生物科技有限公司 | Cdk4/6抑制剂、其药物组合物、制备方法及应用 |
| CN114302722A (zh) | 2019-07-07 | 2022-04-08 | 奥列马制药公司 | 雌激素受体拮抗剂方案 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021022172A1 (en) | 2019-08-01 | 2021-02-04 | Incyte Corporation | A dosing regimen for an ido inhibitor |
| CN116348458A (zh) | 2019-08-14 | 2023-06-27 | 因赛特公司 | 作为cdk2抑制剂的咪唑基嘧啶基胺化合物 |
| CN118986983A (zh) | 2019-08-26 | 2024-11-22 | 阿尔维纳斯运营股份有限公司 | 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法 |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3157681A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| EP4045151A1 (en) | 2019-10-14 | 2022-08-24 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN112759589B (zh) * | 2019-11-01 | 2022-04-08 | 暨南大学 | 嘧啶并吡啶酮类化合物及其应用 |
| US11697648B2 (en) | 2019-11-26 | 2023-07-11 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as JAK inhibitors |
| KR20220108085A (ko) | 2019-12-03 | 2022-08-02 | 제넨테크, 인크. | 유방암 치료를 위한 병용 요법 |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
| EP4077331A4 (en) | 2019-12-16 | 2023-12-27 | Lunella Biotech, Inc. | SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS |
| US12319690B2 (en) * | 2019-12-16 | 2025-06-03 | Lunella Biotech, Inc. | Selective CDK 4/6 inhibitor cancer therapeutics |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20230117684A1 (en) | 2020-03-05 | 2023-04-20 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| EP4114401A1 (en) | 2020-03-06 | 2023-01-11 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| EP4118082A4 (en) * | 2020-03-13 | 2024-05-01 | Prosenestar LLC | PYRIDO[2,3-D]PYRIMIDINE-7(8H)-ONES AS CDK INHIBITORS |
| JP2023518508A (ja) * | 2020-03-27 | 2023-05-01 | 江蘇康寧杰瑞生物制薬有限公司 | 腫瘍を治療するための抗ｈｅｒ２抗体とｃｄｋ阻害剤の組み合わせ |
| JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置 |
| AU2021254794A1 (en) | 2020-04-16 | 2022-12-15 | Incyte Corporation | Fused tricyclic KRAS inhibitors |
| WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
| CN115698014B (zh) | 2020-05-19 | 2025-07-29 | 法码科思莫斯控股有限公司 | 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物 |
| EP4157847A4 (en) * | 2020-05-28 | 2024-06-19 | University of Washington | Drug-like molecules and methods for the therapeutic targeting of viral rna structures |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN113880809B (zh) | 2020-07-03 | 2022-10-18 | 盛世泰科生物医药技术(苏州)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
| AU2021308406A1 (en) | 2020-07-15 | 2023-02-23 | Ctxt Pty Ltd | KAT6 inhibitor methods and combinations for cancer treatment |
| CA3189632A1 (en) | 2020-07-20 | 2022-01-27 | Pfizer Inc. | Combination therapy |
| WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
| WO2022063119A1 (zh) * | 2020-09-24 | 2022-03-31 | 南京济群医药科技股份有限公司 | 一种羟乙磺酸哌柏西利的组合物及药物 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| WO2022091001A1 (en) | 2020-10-29 | 2022-05-05 | Pfizer Ireland Pharmaceuticals | Process for preparation of palbociclib |
| WO2022123419A1 (en) | 2020-12-08 | 2022-06-16 | Pfizer Inc. | Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib |
| CN112569361B (zh) * | 2020-12-30 | 2023-01-10 | 扬子江药业集团上海海尼药业有限公司 | 一种哌柏西利干混悬组合物及其制备方法 |
| WO2022155941A1 (en) | 2021-01-25 | 2022-07-28 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors |
| WO2022162122A1 (en) | 2021-01-29 | 2022-08-04 | Biotx.Ai Gmbh | Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection |
| WO2022206888A1 (en) | 2021-03-31 | 2022-10-06 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| AU2022289202B2 (en) * | 2021-06-09 | 2025-09-25 | Tyk Medicines (Zhengzhou) , Inc. | Compound as cdk kinase inhibitor and use thereof |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2024522188A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| KR20240032915A (ko) | 2021-07-07 | 2024-03-12 | 인사이트 코포레이션 | Kras의 저해제로서의 삼환식 화합물 |
| WO2023287896A1 (en) | 2021-07-14 | 2023-01-19 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| AU2022311961A1 (en) | 2021-07-16 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof |
| TW202320795A (zh) | 2021-07-26 | 2023-06-01 | 美商凱爾科迪股份有限公司 | 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法 |
| JP2024534187A (ja) | 2021-08-31 | 2024-09-18 | インサイト・コーポレイション | Ｋｒａｓの阻害剤としてのナフチリジン化合物 |
| CN113683612B (zh) * | 2021-09-07 | 2022-06-17 | 山东铂源药业股份有限公司 | 一种帕布昔利布的制备方法 |
| CN118119393A (zh) * | 2021-09-14 | 2024-05-31 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| WO2023056421A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| CR20240197A (es) | 2021-10-14 | 2024-08-07 | Incyte Corp | Compuestos de quinolina como inhibidores de kras |
| CA3239205A1 (en) | 2021-11-22 | 2023-05-25 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a kras inhibitor |
| WO2023102184A1 (en) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Bicyclic amine compounds as cdk12 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US20240398832A1 (en) | 2021-12-10 | 2024-12-05 | Eli Lilly And Company | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| WO2023114264A1 (en) | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
| IL313735A (en) | 2021-12-22 | 2024-08-01 | Incyte Corp | Salts and solid forms of Pajfer inhibitor and processes for their preparation |
| WO2023168686A1 (en) | 2022-03-11 | 2023-09-14 | Qilu Regor Therapeutics Inc. | Substituted cyclopentanes as cdk2 inhibitors |
| TW202341982A (zh) | 2021-12-24 | 2023-11-01 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｃｄｋ２抑制劑及其用途 |
| CN114456180B (zh) * | 2022-02-18 | 2023-07-25 | 贵州大学 | 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用 |
| JP2025512710A (ja) | 2022-03-07 | 2025-04-22 | インサイト・コーポレイション | Ｃｄｋ２阻害剤の固体形態、塩、ならびに調製プロセス |
| HU231594B1 (hu) * | 2022-05-10 | 2025-03-28 | Egis Gyógyszergyár Zrt. | Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény |
| TW202413359A (zh) | 2022-06-22 | 2024-04-01 | 美商英塞特公司 | 雙環胺ｃｄｋ１２抑制劑 |
| EP4302755B1 (en) | 2022-07-07 | 2025-08-20 | Lotus Pharmaceutical Co., Ltd. | Palbociclib formulation containing an amino acid |
| EP4302832A1 (en) | 2022-07-07 | 2024-01-10 | Lotus Pharmaceutical Co., Ltd. | Palbociclib formulation containing glucono delta lactone |
| WO2024015731A1 (en) | 2022-07-11 | 2024-01-18 | Incyte Corporation | Fused tricyclic compounds as inhibitors of kras g12v mutants |
| CN117430597A (zh) * | 2022-07-14 | 2024-01-23 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
| CN119604288A (zh) | 2022-07-29 | 2025-03-11 | 辉瑞大药厂 | 用于治疗癌症的包含kat6抑制剂的给药方案 |
| CA3266061A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | DOSING REGIMEN BASED ON ESTROGEN RECEPTOR DEGRADING AGENTS |
| AU2023373671A1 (en) | 2022-11-02 | 2025-05-15 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
| WO2024125581A2 (zh) * | 2022-12-16 | 2024-06-20 | 上海岸阔医药科技有限公司 | 化合物及其用途 |
| WO2024133726A1 (en) | 2022-12-22 | 2024-06-27 | Synthon B.V. | Pharmaceutical composition comprising palbociclib |
| WO2024132652A1 (en) | 2022-12-22 | 2024-06-27 | Synthon B.V. | Pharmaceutical composition comprising palbociclib |
| KR20250164842A (ko) | 2023-03-30 | 2025-11-25 | 화이자 인코포레이티드 | Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법 |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| WO2024220532A1 (en) | 2023-04-18 | 2024-10-24 | Incyte Corporation | Pyrrolidine kras inhibitors |
| AU2024258965A1 (en) | 2023-04-18 | 2025-11-06 | Incyte Corporation | 2-azabicyclo[2.2.1]heptane kras inhibitors |
| TW202508598A (zh) | 2023-05-05 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | 癌症療法 |
| WO2024235844A1 (en) | 2023-05-12 | 2024-11-21 | Institut National de la Santé et de la Recherche Médicale | Methods of preventing on-target genotoxicity induced by nucleases |
| WO2024254245A1 (en) | 2023-06-09 | 2024-12-12 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| WO2025051337A1 (en) | 2023-09-06 | 2025-03-13 | Afyx Development A/S | Compositions and methods for treating and preventing oral cancer |
| WO2025096738A1 (en) | 2023-11-01 | 2025-05-08 | Incyte Corporation | Kras inhibitors |
| WO2025122470A1 (en) | 2023-12-04 | 2025-06-12 | Genentech, Inc. | Combination therapies for treatment of breast cancer |
| US20250195536A1 (en) | 2023-12-13 | 2025-06-19 | Incyte Corporation | Bicyclooctane kras inhibitors |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959474A (en) | 1979-06-14 | 1990-09-25 | Burroughs Wellcome Co. | Dialkoxy pyridopyrimidine compounds |
| NZ194045A (en) | 1979-06-14 | 1984-09-28 | Wellcome Found | 6-(2,5-or 3,4-dialkoxybenzyl)-2,4-diamino-5-methylpyrido(2,3-d)pyrimidines |
| ZA803539B (en) | 1979-06-14 | 1982-01-27 | Wellcome Found | Alkoxybenzylrimidines method for their preparation formulation thereof and their use in medicine |
| AU598093B2 (en) | 1987-02-07 | 1990-06-14 | Wellcome Foundation Limited, The | Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
| DK0584222T3 (da) | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase |
| US5426110A (en) | 1993-10-06 | 1995-06-20 | Eli Lilly And Company | Pyrimidinyl-glutamic acid derivatives |
| GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
| CZ286160B6 (cs) | 1994-11-14 | 2000-01-12 | Warner-Lambert Company | 6-Arylpyrido[2,3-d]pyrimidiny a naftyridiny a farmaceutické prostředky na jejich bázi |
| US5801183A (en) | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| CA2250943A1 (en) | 1996-04-12 | 1997-10-23 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| AU749750B2 (en) * | 1997-02-05 | 2002-07-04 | Warner-Lambert Company | Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| ATE332896T1 (de) | 1997-10-27 | 2006-08-15 | Agouron Pharma | 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin- abhängiger kinasen |
| ID27589A (id) * | 1998-05-26 | 2001-04-12 | Warner Lambert Comapny | Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular |
| JP2002523497A (ja) | 1998-08-29 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | ピリミジン化合物 |
| US6958333B1 (en) | 1999-07-26 | 2005-10-25 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| EP1409487A1 (en) | 1999-09-15 | 2004-04-21 | Warner-Lambert Company Llc | Pteridinones as kinase inhibitors |
| CZ20022521A3 (cs) * | 2000-01-27 | 2003-02-12 | Warner-Lambert Company | Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění |
| NZ520962A (en) * | 2000-03-06 | 2003-09-26 | Warner Lambert Co | 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors |
| AU2001277032A1 (en) * | 2000-08-04 | 2002-02-18 | Warner Lambert Company | 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7 ones |
| DE60106947T2 (de) | 2000-09-01 | 2005-11-10 | Glaxo Group Ltd., Greenford | Oxindolderivate |
| GB0101686D0 (en) | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
| PL366918A1 (en) * | 2001-02-12 | 2005-02-07 | F.Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| DE60210819T2 (de) | 2001-12-17 | 2007-04-19 | Smithkline Beecham Corp. | Pyrazolopyridazinderivate |
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| EP1551813A4 (en) | 2002-10-10 | 2007-07-11 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| AP1967A (en) | 2002-11-22 | 2009-03-10 | Smithkline Beecham Corp | Thiazolidinone compounds as inhibitors of Hyak3 |
| US20050009849A1 (en) * | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| JP2006519234A (ja) | 2003-02-27 | 2006-08-24 | スミスクライン ビーチャム コーポレーション | 新規化合物 |
| SI1648889T1 (sl) | 2003-07-11 | 2009-02-28 | Warner Lambert Co | Izetionatna sol selektivnega CDK4 inhibitorja |
| EP2069344A2 (en) | 2006-09-08 | 2009-06-17 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
-
2003
- 2003-01-10 MX MXPA04005939A patent/MXPA04005939A/es active IP Right Grant
- 2003-01-10 CN CN038025566A patent/CN101001857B/zh not_active Expired - Lifetime
- 2003-01-10 EP EP03700058A patent/EP1470124B1/en not_active Expired - Lifetime
- 2003-01-10 RS YUP-598/04A patent/RS51044B/sr unknown
- 2003-01-10 KR KR1020047011276A patent/KR100669578B1/ko not_active Expired - Lifetime
- 2003-01-10 KR KR1020067018532A patent/KR20060111716A/ko not_active Withdrawn
- 2003-01-10 AP APAP/P/2004/003085A patent/AP1767A/en active
- 2003-01-10 HR HRP20040660AA patent/HRP20040660B1/hr not_active IP Right Cessation
- 2003-01-10 CN CN2011101150746A patent/CN102295643B/zh not_active Expired - Lifetime
- 2003-01-10 EA EA200400860A patent/EA007395B3/ru active Protection Beyond IP Right Term
- 2003-01-10 PL PL372046A patent/PL218692B1/pl unknown
- 2003-01-10 AT AT03700058T patent/ATE314370T1/de active
- 2003-01-10 DK DK03700058T patent/DK1470124T3/da active
- 2003-01-10 NZ NZ534069A patent/NZ534069A/en not_active IP Right Cessation
- 2003-01-10 AU AU2003237009A patent/AU2003237009B2/en active Active
- 2003-01-10 SI SI200330164T patent/SI1470124T1/sl unknown
- 2003-01-10 ES ES03700058T patent/ES2251677T3/es not_active Expired - Lifetime
- 2003-01-10 CA CA2473026A patent/CA2473026C/en not_active Expired - Lifetime
- 2003-01-10 PL PL391191A patent/PL220952B1/pl unknown
- 2003-01-10 CN CN2010102557666A patent/CN101906104B/zh not_active Expired - Lifetime
- 2003-01-10 DE DE60303009T patent/DE60303009T2/de not_active Expired - Lifetime
- 2003-01-10 IL IL16272103A patent/IL162721A0/xx unknown
- 2003-01-10 JP JP2003562114A patent/JP4291696B2/ja not_active Expired - Lifetime
- 2003-01-10 WO PCT/IB2003/000059 patent/WO2003062236A1/en not_active Ceased
- 2003-01-10 BR BR122016021801A patent/BR122016021801B8/pt not_active IP Right Cessation
- 2003-01-10 OA OA1200400189A patent/OA12755A/en unknown
- 2003-01-10 GE GE5674A patent/GEP20063909B/en unknown
- 2003-01-10 BR BRPI0307057A patent/BRPI0307057B8/pt active IP Right Grant
- 2003-01-10 ME MEP-461/08A patent/MEP46108A/xx unknown
- 2003-01-14 DO DO2003000561A patent/DOP2003000561A/es unknown
- 2003-01-14 NI NI200300008A patent/NI200300008A/es unknown
- 2003-01-16 PE PE2003000050A patent/PE20030975A1/es active IP Right Grant
- 2003-01-16 US US10/345,778 patent/US6936612B2/en not_active Expired - Lifetime
- 2003-01-17 GT GT200300005A patent/GT200300005A/es unknown
- 2003-01-20 AR ARP030100158A patent/AR038814A1/es active IP Right Grant
- 2003-01-20 MY MYPI20030182A patent/MY134818A/en unknown
- 2003-01-21 TW TW092101242A patent/TWI343920B/zh active
- 2003-01-21 SV SV2003001459A patent/SV2004001459A/es not_active Application Discontinuation
- 2003-01-21 UY UY27617A patent/UY27617A1/es not_active Application Discontinuation
- 2003-01-21 HN HN2003000039A patent/HN2003000039A/es unknown
- 2003-01-22 PA PA20038563701A patent/PA8563701A1/es unknown
- 2003-10-01 UA UA20040706104A patent/UA79444C2/uk unknown
-
2004
- 2004-06-16 IS IS7323A patent/IS2423B/is unknown
- 2004-06-18 ZA ZA2004/04840A patent/ZA200404840B/en unknown
- 2004-06-24 IL IL162721A patent/IL162721A/en active Protection Beyond IP Right Term
- 2004-07-07 TN TNP2004000126A patent/TNSN04126A1/fr unknown
- 2004-07-15 MA MA27785A patent/MA27166A1/fr unknown
- 2004-07-22 EC EC2004005201A patent/ECSP045201A/es unknown
- 2004-07-22 CO CO04069500A patent/CO5700765A2/es not_active Application Discontinuation
- 2004-08-20 NO NO20043484A patent/NO329350B1/no not_active IP Right Cessation
-
2005
- 2005-01-28 US US11/046,126 patent/US7208489B2/en not_active Ceased
-
2006
- 2006-03-08 CY CY20061100324T patent/CY1105686T1/el unknown
-
2007
- 2007-04-11 US US11/734,200 patent/US7456168B2/en not_active Expired - Lifetime
-
2009
- 2009-04-20 IL IL198243A patent/IL198243A/en active IP Right Grant
-
2010
- 2010-01-05 EC EC2010005201A patent/ECSP105201A/es unknown
-
2011
- 2011-11-02 AR ARP110104062A patent/AR083686A2/es active IP Right Grant
-
2012
- 2012-03-19 CR CR20120129A patent/CR20120129A/es unknown
-
2017
- 2017-03-01 NL NL300863C patent/NL300863I2/nl unknown
- 2017-03-01 HU HUS1700009C patent/HUS1700009I1/hu unknown
- 2017-03-15 LU LU00009C patent/LUC00009I2/en unknown
- 2017-03-16 BE BE2017C005C patent/BE2017C005I2/fr unknown
- 2017-03-17 CY CY2017011C patent/CY2017011I2/el unknown
- 2017-04-19 NO NO2017014C patent/NO2017014I2/no unknown
- 2017-04-19 FR FR17C1012C patent/FR17C1012I2/fr active Active
- 2017-04-28 LT LTPA2017013C patent/LTC1470124I2/lt unknown
- 2017-05-04 HU HUS1700019C patent/HUS1700019I1/hu unknown
-
2018
- 2018-07-27 US US16/048,143 patent/USRE47739E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00230B (me) | 2-(piridin -2-ilamino)-pirido(2,3-d) pirimidin-7-oni | |
| JP7579402B2 (ja) | 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物 | |
| CA2576269C (en) | Combinations for the treatment of diseases involving cell proliferation | |
| CA3124678A1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| CN114732910B (zh) | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd | |
| JP2008528468A5 (show.php) | ||
| CA3034705A1 (en) | Inhibitors of cellular metabolic processes | |
| ES2652514T3 (es) | Compuestos heteroaromáticos como ligandos de dopamina D1 | |
| CA2778686C (en) | N-9-substituted purine compounds, compositions and methods of use | |
| JP2012511588A5 (show.php) | ||
| CN114599361A (zh) | Prmt5抑制剂的药物组合物 | |
| PH12012501386A1 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| JP2019524872A (ja) | 癌の治療に有用なイミダゾピリミジン化合物 | |
| CA2817460A1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| SG146694A1 (en) | 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo-2,3-c pyridin-2- ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes | |
| CA2782213A1 (en) | 1,7-diazacarbazoles and their use in the treatment of cancer | |
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| JP7603740B2 (ja) | シクロオレフィン置換複素芳香族化合物およびそれらの使用 | |
| HRP20250969T1 (hr) | Triciklički parp1 inhibitori i njihove uporabe | |
| JP2013511526A5 (show.php) | ||
| CN104447765A (zh) | 三环化合物及其药物组合物和应用 | |
| HRP20151419T1 (hr) | Derivati 2-okso-1-imidazolidinil imidazotiadiazola | |
| RU2012138162A (ru) | Производные пиридазина для использования в качестве агонистов каннабинода-2 | |
| RU2020120538A (ru) | Производные пиридинона и их применение в качестве селективных ингибиторов alk-2 | |
| RU2006138864A (ru) | Ингибиторы митотического кинезина |